Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2026 16:05 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026

CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
March 11, 2026 08:15 ET | Source: Portillo’s Inc.

Eugene I. Lee, Jr. Appointed Chairman of the Board of Portillo’s; Michael A. Miles, Jr. to Retire as of Annual Meeting

CHICAGO, March 11, 2026 (GLOBE NEWSWIRE) -- Portillo’s (NASDAQ: PTLO), the fast-casual restaurant concept known for its menu of Chicago-style favorites, today announced a leadership transition...
March 11, 2026 07:53 ET | Source: Janssen Cilag International NV

La Commission européenne approuve AKEEGA® (comprimé à double action de niraparib et d’acétate d’abiratérone) pour le traitement des patients atteints d’un cancer de la prostate hormonosensible métastatique (CPHSm) présentant des mutations BRCA1/2

Le traitement par niraparib et acétate d’abiratérone démontre un retard cliniquement significatif dans la progression de la maladie, réduisant de près de moitié le risque de progression ou de décès,...
March 09, 2026 06:23 ET | Source: Janssen Cilag International NV

European Commission approves AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer (mHSPC)

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall...
February 26, 2026 16:05 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET

NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal...
February 06, 2026 07:30 ET | Source: Plains All American Pipeline, L.P.; Plains GP Holdings

Plains All American Reports Fourth-Quarter and Full-Year 2025 Results

HOUSTON, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Plains All American Pipeline, L.P. (Nasdaq: PAA) and Plains GP Holdings (Nasdaq: PAGP) today reported fourth-quarter and full-year 2025 results, announced...
February 06, 2026 06:13 ET | Source: Janssen Cilag International NV

Johnson & Johnson reçoit un avis favorable du CHMP pour AKEEGA® (comprimé à double action de niraparib et d’acétate d’abiratérone) pour le traitement des patients atteints d’un cancer de la prostate hormonosensible métastatique (CPHSm) présentant des mutations BRCA1/2

AMPLITUDE est le premier essai clinique à évaluer des thérapies potentielles pour les patients atteints de CPHSm et d’altérations connues des gènes HRR. Les résultats démontrent un bénéfice clinique...
February 06, 2026 06:13 ET | Source: Janssen Cilag International NV

Johnson & Johnson erhält vom CHMP einen positiven Bescheid für AKEEGA® (Niraparib- und Abirateronacetat-Tablette mit zweifacher Wirkung) zur Behandlung von metastasiertem hormonsensiblen Prostatakrebs (mHSPC) mit BRCA1/2-Mutationen

AMPLITUDE ist die erste klinische Studie für die Evaluation potenzieller Therapien für Patienten mit mHSPC und bekannten HRR-Genveränderungen, einschließlich positiver Ergebnisse, welche die...
February 03, 2026 09:00 ET | Source: Arax Investment Partners

Arax Investment Partners Acquires $1.5 Billion GFP Private Wealth

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- In a move to expand its foothold in the Midwest, Arax Investment Partners (“Arax”), a premier wealth management firm, has acquired GFP Private Wealth...
January 30, 2026 07:19 ET | Source: Janssen Cilag International NV

Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene alterations, with positive results supporting the niraparib-based combination regimen...